Abiraterone - CB 7598

Based on 12 reference(s) in Google Scholar91012

Axon 1873

CAS [154229-19-3]

MF C24H31NOMW 349.51

Purity:100%
Optical purity:Optically pure
Moderately soluble in DMSO

Abiraterone

Description

Inhibitor of the steroidal enzyme 17 α-hydroxylase/C17,20 lyase (CYP17A1); a drug used in castration-resistant prostate cancer (CRPC); active component of its formulated prodrug abiraterone acetate (Axon 1874), which is also available

References
Certificates
Categories
Extra info

G Attard et al. Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer. BJU Int. 2005, 96 (9), 1241–1246.

JE Ang et al. CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependence in castration-resistant prostate cancer. Br. J. Cancer 2009, 100(5), 671–675.

Certificate of Analysis
Material Safety Data Sheet

Cell Signaling & OncologyDiabetes & MetabolismEndocrinologyEC 1.14.99.9Cytochrome P450

Inhibitor of CYP17A1

Chemical name

(3S,8R,9S,10R,13S,14S)-10,13-dimethyl-17-(pyridin-3-yl)-2,3,4,7,8,9,10,11,12,13,14,15-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol

Parent CAS No.

[154229-19-3]

品牌介绍

Axon Medchem的业务之一，是独有的Axon Ligands配体库，在世界范围内，被认为是药物研发的标准。这其中，针对850余种生物靶标（包括细胞信号、基因转录、凋亡、细胞周期调控、CNS等），Axon Medchem拥有多达2000余种小分子抑制剂或调节剂。除了配体库，Axon Medchem还是欧洲著名的CRO公司，主要针对生物活性分子和药物类似分子展开合成及协议开发工作，在过去的10年中，Axon Medchem已经发现了多种潜在药物分子，并在生物医药界享有一定的声誉。

公司介绍

更多...

产品分类

更多...

Enzymes Biomarkers & Labeling reagents Receptors Transcription Factors Assorted Products Axon Ligand™ Sets Ion Channels Proteins

销售排行

更多...